A review of the clinical pharmacology of a new class of oral hypoglycemic drugs, sodium-glucose cotransporter-2 inhibitors (SGLT-2 inhibitors, or gliflozins), is presented. The main mechanism of action of SGLT-2, as well as other metabolic, cardiovascular, and renal effects, which are classified as pleiotropic class effects, is described. Data on the pharmacodynamics and pharmacokinetics of drugs (dapagliflozin, cancgliflozin, empagliflozin, ertugliflozin, ipragliflozin, luseogliflozin, sotagliflozin), side effects and drug interactions are discussed. Data on the clinical pharmacology of the SGLT-2 class will contribute to a better understanding of the underlying mechanism of action and pleiotropic effects that provide cardioprotective and renoprotective effects.

Keywords: sodium-glucose cotransporter-2 inhibitors, clinical pharmacology, drug interactions, pharmacokinetics, pleiotropic effects, side effects